Baudax Stock Analysis

BXRX
 Stock
  

USD 0.25  0.02  8.70%   

The big decline in price over the last few months for Baudax Bio could raise concerns from investors as the firm is trading at a share price of 0.25 on 663,200 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in September. However, diversifying your holdings with Baudax Bio or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.09. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Baudax Bio partners.
Continue to Trending Equities.
  
The Baudax Bio stock analysis report makes it easy to digest most publicly released information about Baudax Bio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Baudax Stock analysis module also helps to analyze the Baudax Bio price relationship with some important fundamental indicators such as market cap and management efficiency.

Baudax Stock Analysis Notes

About 20.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Baudax Bio recorded a loss per share of 1.05. The entity had not issued any dividends in recent years. The firm had a split on the 16th of February 2022. Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. Baudax Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. For more info on Baudax Bio please contact the company at 484 395 2440 or go to https://www.baudaxbio.com.

Baudax Bio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Baudax Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Baudax Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Baudax Bio generated a negative expected return over the last 90 days
Baudax Bio has high historical volatility and very poor performance
Baudax Bio has some characteristics of a very speculative penny stock
Baudax Bio has a very high chance of going through financial distress in the upcoming years
The company currently holds 9.62 M in liabilities with Debt to Equity (D/E) ratio of 0.99, which is about average as compared to similar companies. Baudax Bio has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Baudax Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Baudax Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Baudax Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Baudax to invest in growth at high rates of return. When we think about Baudax Bio's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 1.3 M. Net Loss for the year was (18.09 M) with loss before overhead, payroll, taxes, and interest of (1.36 M).
Baudax Bio currently holds about 11.53 M in cash with (48.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.benzinga.com: Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock - Baudax Bio - Benzinga

Baudax Bio Upcoming and Recent Events

Earnings reports are used by Baudax Bio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Baudax Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report15th of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End15th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Baudax Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Baudax Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Baudax Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Baudax Bio specific information freely available to individual and institutional investors to make a timely investment decision.
6th of September 2022
Unclassified Corporate Event
View
31st of August 2022
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
24th of August 2022
Financial Statements and Exhibits. Material Modifications to Rights of Security Holders
View
23rd of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
3rd of August 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
8th of July 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
27th of June 2022
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant
View

Baudax Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Baudax Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Baudax Bio backward and forwards among themselves. Baudax Bio's institutional investor refers to the entity that pools money to purchase Baudax Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Alyeska Investment Group LpCommon Shares460 K389 K
Renaissance Technologies LlcCommon Shares320.2 K271 K
Walleye Capital LlcCommon Shares195.1 K165 K
Geode Capital Management LlcCommon Shares65.6 K55 K
Vanguard Group IncCommon Shares59.4 K50 K
Sabby Management LlcCommon Shares47.1 K40 K
Warberg Asset Management LlcCommon Shares34.5 K29 K
Note, although Baudax Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Baudax Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 21.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baudax Bio's market, we take the total number of its shares issued and multiply it by Baudax Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (54.79) % which means that it has lost $54.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (358.12) %, meaning that it created substantial loss on money invested by shareholders. Baudax Bio management efficiency ratios could be used to measure how well baudax bio manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of October, Baudax Bio shows the risk adjusted performance of (0.24), and Mean Deviation of 3.99. Baudax Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Baudax Bio, which can be compared to its rivals. Please confirm Baudax Bio variance and potential upside to decide if Baudax Bio is priced correctly, providing market reflects its regular price of 0.25 per share. As Baudax Bio appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Baudax Bio Price Movement Analysis

Study
The minimum time period for execution of this function requires larger time horizon. Please increase the time horizon for this function. The output start index for this execution was zero with a total number of output elements of zero. The Instantaneous Trendline is a moving-average-like indicator which is formed by removing the Dominant Cycle from Baudax Bio price series.
.

Baudax Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Baudax Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Baudax Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Baudax Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Baudax Bio Predictive Daily Indicators

Baudax Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Baudax Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Baudax Bio Forecast Models

Baudax Bio time-series forecasting models is one of many Baudax Bio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Baudax Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Baudax Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Baudax Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Baudax shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Baudax Bio. By using and applying Baudax Stock analysis, traders can create a robust methodology for identifying Baudax entry and exit points for their positions.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. Baudax Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Current Baudax Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Baudax analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Baudax analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
1.83Strong Buy3Odds
Baudax Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Baudax analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Baudax stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Baudax Bio, talking to its executives and customers, or listening to Baudax conference calls.
Baudax Analyst Advice Details

Baudax Stock Analysis Indicators

Baudax Bio stock analysis indicators help investors evaluate how Baudax Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Baudax Bio shares will generate the highest return on investment. By understating and applying Baudax Bio stock analysis, traders can identify Baudax Bio position entry and exit signals to maximize returns.
Quick Ratio0.60
Fifty Two Week Low0.2500
Revenue Growth113.10%
Shares Short Prior Month449.54k
Average Daily Volume Last 10 Day2.14M
Average Daily Volume In Three Month1.61M
Shares Percent Shares Out1.78%
Gross Margins-74.23%
Short Percent Of Float1.80%
Forward Price Earnings-0.18
Float Shares6.03M
Fifty Two Week High22.4000
Enterprise Value To Ebitda-0.05
Fifty Day Average0.5688
Two Hundred Day Average2.9124
Enterprise Value To Revenue2.00
Continue to Trending Equities. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for analysis

When running Baudax Bio price analysis, check to measure Baudax Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baudax Bio is operating at the current time. Most of Baudax Bio's value examination focuses on studying past and present price action to predict the probability of Baudax Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Baudax Bio's price. Additionally, you may evaluate how the addition of Baudax Bio to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Baudax Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Baudax Bio. If investors know Baudax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Baudax Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Baudax Bio is measured differently than its book value, which is the value of Baudax that is recorded on the company's balance sheet. Investors also form their own opinion of Baudax Bio's value that differs from its market value or its book value, called intrinsic value, which is Baudax Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Baudax Bio's market value can be influenced by many factors that don't directly affect Baudax Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Baudax Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Baudax Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Baudax Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.